Orchestra BioMed Holdings, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing is by Health Sciences Acquisitions Corporation 2 (HSAQ), a blank-check company that proposed combining with Orchestra BioMed, Inc. HSAQ expected to rename itself Orchestra BioMed Holdings, Inc. upon closing; this filing does not report Orchestra BioMed’s operating results.
Business context and transaction status
HSAQ was formed to pursue a business combination, with a stated focus on healthcare innovation. It had not begun operations or generated operating revenue by year-end. On July 4, 2022, it agreed to combine with Orchestra BioMed through a domestication and merger.
Shareholders approved the combination at a January 24, 2023 meeting. As of that date, holders had requested redemption of 1,597,888 public shares at approximately $10.02 per share. The filing, signed January 25, 2023, said closing was anticipated in January 2023; it does not establish that the transaction ultimately closed.
Financial results and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Operating revenue | None | None |
| General and administrative expenses | $2.96 million | $275,000 |
| Administrative fee to sponsor | $120,000 | $120,000 |
| Interest income from trust investments | $345,000 | $16,000 |
| Net loss | $2.74 million | $379,000 |
| Basic and diluted loss per share | $0.17 | $0.02 |
| Net cash used in operating activities | $1.58 million | $272,000 |
The larger year-over-year loss reflected substantially higher general and administrative costs, partly offset by increased trust-account interest. Margins are not meaningful because HSAQ had no revenue. Operating cash fell to $175,000 from $1.75 million.
At December 31, 2022, HSAQ reported total assets of $68.08 million, including $67.78 million in trust-account cash; total liabilities of $7.34 million, including $5.60 million of deferred underwriting commissions; and a $1.74 million working-capital deficit. No working-capital loans were outstanding. The trust balance was held for public shareholders and was not equivalent to cash available for ordinary operating expenses.
Material changes, outlook, risks and unusual items
- At the July 2022 extension vote, 9,237,883 public shares were redeemed for approximately $92.6 million, or about 57.7% of public shares. The trust balance afterward was approximately $67.8 million.
- The RTW Funds purchased 1,000,000 HSAQ shares from an investor at $10.01 per share in July 2022. RTW and an affiliate of Medtronic each agreed to forward-purchase approximately $10 million of shares, subject to terms. RTW also agreed to backstop closing cash if it fell below $60 million, inclusive of the specified RTW forward-purchase commitment. The filing does not state the final amount funded under these arrangements.
- Management and the auditor identified substantial doubt about HSAQ’s ability to continue as a going concern, citing limited operating cash, the working-capital deficit and the February 6, 2023 business-combination deadline. If no combination were completed by the deadline, HSAQ faced liquidation. The financial statements contain no liquidation adjustments.
- HSAQ reported no material litigation and no off-balance-sheet arrangements. Management said geopolitical and market uncertainty could affect the search and transaction, but the specific impact was not readily determinable.
- The sponsor agreed to forfeit 750,000 private warrants at closing and potentially forfeit 1,000,000 shares five years after closing unless specified share-price hurdles were met. The filing provides no operating guidance or revenue outlook for the proposed combined company.
Important facts for investors to verify
- Whether and when the Orchestra BioMed business combination closed, and the final post-redemption trust cash and closing cash available to the combined company.
- The final number of shares redeemed at the January 2023 meeting and the resulting ownership, dilution and liquidity profile.
- Whether the RTW and Medtronic forward purchases and RTW backstop were funded, and the final terms and cash proceeds.
- Orchestra BioMed’s operating performance, cash needs, financing commitments and outlook in the applicable post-combination filings; this 10-K does not provide those results.
- The treatment of deferred underwriting commissions, warrants, sponsor forfeitures and other transaction-related dilution at closing.